Next-Generation Immuno-Oncology Solutions
Immuno-oncology (I/O) therapies are considered to be promising anti-cancer treatments and are generating hope and excitement among researchers, clinicians, and patients. Our Ion Torrent sequencing platform combined with our proven AmpliSeq technology bring accuracy, sensitivity, and ease of use when working with oncology samples, providing a superior solution for your immuno-oncology research.
How does Ion AmpliSeq technology work?
How does the Ion S5 System work?
The Ion Torrent immuno-sequencing solution is designed to help identify markers relevant to immunotherapies using our streamlined sequencing platform and fully integrated informatics solutions to analyze and interpret results.
Each individual assay enables you to interrogate the specific elements of the cancer immunity cycle—and when combined, they provide a holistic view and deeper understanding of the biology within the tumor microenvironment to enhance clinical research study design and positively impact study outcomes.
Oncomine Immune Response Research Assay
Designed to interrogate the tumor microenvironment (TME) and enable mechanistic studies for the identification of biomarkers relevant to immunotherapies.
Ion AmpliSeq Immune Repertoire Assay Plus, TCR beta
A long-read next-generation sequencing (NGS) assay designed to measure T cell diversity and clonal expansion by sequencing T cell receptor beta chain rearrangements, and provide researchers with a rapid NGS tool for studying the complexity of cellular immunology.
Oncomine Tumor Mutation Load Assay
Designed to provide clinical researchers with a quantifiable assessment of tumor mutation load and to identify the mutational load for biomarkers associated with relevant immunotherapies.